Tagged with Sandoz

Novartis Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames of rumours that parent company Novartis is planning a spinoff or sale for its generics arm.   This is a multi-year journey which I cannot commit to and therefore…

Malaysia Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company in Malaysia as well as the importance of a manager working closely with his team to achieve growth.   Malaysia…

Turkey Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical industry and the government.   Through its Sandoz division, Novartis has been in Turkey since 1930 Can you introduce the…

Algeria Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies to ensure sustainability within the Algerian market.   You’ve been in Algeria for four years. Can you enlighten our viewers…

Spain Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines the rationale behind the creation of a national biosimilars association, BioSim.   Can you please start by introducing Sandoz and…

Canada Having just announced the first collaboration between a medical cannabis company and a major pharmaceutical player, Tilray expects to launch its first co-branded product with Sandoz Canada by the end of the year. Tilray’s founder and CEO Brendan Kennedy highlights the company’s main differentiation factors, including but not limited to…

UK Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners with the NHS. In addition to your role at Sandoz, you are also one of the founding members of the…

Baltics Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration with key stakeholders to enhance the uptake of biosimilars. Roland, prior to joining Sandoz as Cluster Head Baltics you were…

Canada Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio in the four business segments of generics, biosimilars, consumer (OTC) and specialty products. He talks about the quality of the…

Philippines Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped to expand access to affordable medications to the Filipinos, still pointing out that there is much room for expansion in…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Pharma Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing Sandoz’s historic engagement with the Italian market? Sandoz began marketing in Italy back in 2000. My own background, meanwhile, was…